In the past week, PFE stock has gone up by 3.52%, with a monthly decline of -9.08% and a quarterly plunge of -12.15%. The volatility ratio for the week is 2.50%, and the volatility levels for the last 30 days are 3.46% for Pfizer Inc The simple moving average for the past 20 days is -0.11% for PFE’s stock, with a -15.33% simple moving average for the past 200 days.
Is It Worth Investing in Pfizer Inc (NYSE: PFE) Right Now?
Pfizer Inc (NYSE: PFE) has a higher price-to-earnings ratio of 16.28x compared to its average ratio, The 36-month beta value for PFE is at 0.56. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 15 as “hold,” and 1 as “sell.”
The public float for PFE is 5.67B, and currently, shorts hold a 1.90% of that float. The average trading volume for PFE on April 28, 2025 was 51.09M shares.
PFE) stock’s latest price update
Pfizer Inc (NYSE: PFE)’s stock price has plunge by 0.61relation to previous closing price of 22.78. Nevertheless, the company has seen a 3.52% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-27 that Pfizer’s Q1 earnings release is a prime opportunity to secure about a 7.55% dividend yield, with revenue stabilizing post-pandemic and strong cost efficiency. Pfizer’s robust product pipeline and consistent R&D investments position it well for future growth, despite past revenue volatility from COVID-19. Valuation metrics indicate Pfizer stock is significantly undervalued, with crucial ratios like Price/Book and Price/Cash Flow much lower than industry averages.
Analysts’ Opinion of PFE
Many brokerage firms have already submitted their reports for PFE stocks, with Cantor Fitzgerald repeating the rating for PFE by listing it as a “Neutral.” The predicted price for PFE in the upcoming period, according to Cantor Fitzgerald is $24 based on the research report published on April 22, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see PFE reach a price target of $29. The rating they have provided for PFE stocks is “Neutral” according to the report published on December 10th, 2024.
Wolfe Research gave a rating of “Underperform” to PFE, setting the target price at $25 in the report published on November 15th of the previous year.
PFE Trading at -7.55% from the 50-Day Moving Average
After a stumble in the market that brought PFE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.33% of loss for the given period.
Volatility was left at 3.46%, however, over the last 30 days, the volatility rate increased by 2.50%, as shares sank -8.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.01% lower at present.
During the last 5 trading sessions, PFE rose by +3.52%, which changed the moving average for the period of 200-days by -17.32% in comparison to the 20-day moving average, which settled at $22.95. In addition, Pfizer Inc saw -13.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PFE starting from DAMICO JENNIFER B., who sale 2,500 shares at the price of $25.93 back on Mar 04 ’25. After this action, DAMICO JENNIFER B. now owns 11,850 shares of Pfizer Inc, valued at $64,825 using the latest closing price.
BLAYLOCK RONALD E, the Director of Pfizer Inc, purchase 19,457 shares at $25.65 during a trade that took place back on Feb 13 ’25, which means that BLAYLOCK RONALD E is holding 27,707 shares at $499,072 based on the most recent closing price.
Stock Fundamentals for PFE
Current profitability levels for the company are sitting at:
- 0.23 for the present operating margin
- 0.66 for the gross margin
The net margin for Pfizer Inc stands at 0.13. The total capital return value is set at 0.09. Equity return is now at value 9.05, with 3.65 for asset returns.
Based on Pfizer Inc (PFE), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.2. The debt to equity ratio resting at 0.72. The interest coverage ratio of the stock is 4.82.
Currently, EBITDA for the company is 18.13 billion with net debt to EBITDA at 3.45. When we switch over and look at the enterprise to sales, we see a ratio of 3.03. The receivables turnover for the company is 4.31for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.17.
Conclusion
In conclusion, Pfizer Inc (PFE) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
